Atlas of Metastatic Gastric Cancer Links Ferroptosis to Disease Progression and Immunotherapy Response
Xiangdong Cheng,Enyu Dai,Jibo Wu,Natasha M Flores,Yanshuo Chu,Ruiping Wang,Minghao Dang,Zhiyuan Xu,Guangchun Han,Yunhe Liu,Deyali Chatterjee,Can Hu,Jieer Ying,Yian Du,Litao Yang,Xiaoqing Guan,Shaowei Mo,Xuanye Cao,Guangsheng Pei,Jiahui Jiang,Xiaoyin Lu,Ana Morales Benitez,Rebecca E Waters,Melissa Pool Pizzi,Namita Shanbhag,Yibo Fan,Fuduan Peng,Samir M Hanash,George Calin,Andrew Futreal,Shumei Song,Cassian Yee,Pawel K Mazur,Jiang-Jiang Qin,Jaffer A Ajani,Linghua Wang
DOI: https://doi.org/10.1053/j.gastro.2024.07.038
IF: 29.4
2024-08-02
Gastroenterology
Abstract:Background & aims: Metastases from gastric adenocarcinoma (GAC) lead to high morbidity and mortality. Developing innovative and effective therapies requires a comprehensive understanding of the tumor and immune biology of advanced GAC. Yet, collecting matched specimens from advanced, treatment-naïve patients with GAC poses a significant challenge, limiting the scope of current research, which has focused predominantly on localized tumors. This gap hinders deeper insight into the metastatic dynamics of GAC. Methods: We performed in-depth single-cell transcriptome and immune profiling on 68 paired, treatment-naïve, primary metastatic tumors to delineate alterations in cancer cells and their tumor microenvironment during metastatic progression. To validate our observations, we conducted comprehensive functional studies both in vitro and in vivo, using cell lines and multiple patient-derived xenograft and novel mouse models of GAC. Results: Liver and peritoneal metastases exhibited distinct properties in cancer cells and dynamics of tumor microenvironment phenotypes, supporting the notion that cancer cells and their local tumor microenvironments co-evolve at metastatic sites. Our study also revealed differential activation of cancer meta-programs across metastases. We observed evasion of cancer cell ferroptosis via GPX4 up-regulation during GAC progression. Conditional depletion of Gpx4 or pharmacologic inhibition of ferroptosis resistance significantly attenuated tumor growth and metastatic progression. In addition, ferroptosis-resensitizing treatments augmented the efficacy of chimeric antigen receptor T-cell therapy. Conclusions: This study represents the largest single-cell dataset of metastatic GACs to date. High-resolution mapping of the molecular and cellular dynamics of GAC metastasis has revealed a rationale for targeting ferroptosis defense in combination with chimeric antigen receptor T-cell therapy as a novel therapeutic strategy with potential immense clinical implications.